Rationale and Design of the German-Speaking Myeloma Multicenter Group (GMMG) Trial HD6: A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction/Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
BMC Cancer - United Kingdom
doi 10.1186/s12885-019-5600-x
Full Text
Open PDFAbstract
Available in full text
Date
May 28, 2019
Authors
Publisher
Springer Science and Business Media LLC